One of the highlights of Eli Lilly's third-quarter results ... said Lilly's chief financial officer Anat Ashkenazi on the call. Now, Lilly's focus is on international expansion – with approvals ...

With measles on the rise, this episode of Uncanny Valley looks at RFK Jr.’s role in the revival of the once-eliminated deadly illness.

While many pharma and biotech companies developing drugs to treat Alzheimer's disease are targeting amyloid beta plaque, Eli ...

Eli Lilly’s total deal value with Rznomics could exceed $1.3 billion, plus royalties. Rznomics will lead early-stage research; Lilly to handle development and sales. Don’t miss this list of 3 ...

Meanwhile, Eli Lilly's Zepbound injection has gained traction, prompting both firms to race toward more convenient weight?loss pills. Investors will watch upcoming trial readouts and regulatory ...

Eli Lilly recently announced the impressive results of its SURMOUNT-5 trial, highlighting Zepbound's efficacy over Wegovy in weight management. This promising development was disclosed alongside ...

The momentum is now with Lilly. Visible Alpha, a data firm, expects its sales of obesity drugs to overtake Novo’s by 2027 ...

Positive results for Eli Lilly's new diabetes and weight-loss drug have recently boosted its stock price. Data from several studies on the GLP-1 drug are expected to come out this year.

Year-to-date, both Novo Nordisk (NYSE:NVO) and Eli Lilly (NYSE:LLY) delivered negative stock performance, at -26.5% and -6.7%, respectively. In recent years, these pharma giants have become even ...

Eli Lilly’s expanding US production and advancing pipeline offset near-term headwinds and support bullish conviction. Read why LLY stock is a buy.